PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Researchers say work lays the foundation for a first-line, deployable antiviral platform that is virus agnostic and modular.

Antimicrobial resistance studies often focus on individual protein variants, neglecting broader protein family dynamics. Dihydrofolate reductase (DHFR), a key antibiotic target, has been extensively ...

Absci and Almirall have expanded their 21-month-old AI-based collaboration to develop and commercialize therapeutics for chronic skin diseases.

The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.